EMD Serono, a subsidiary of Merck, and Pfizer have announced the FDA approval of Rebif Rebidose (interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). Rebif Rebidose was designed as single-use auto-injector ...
Nuron Biotech has secured $80m finance from HealthCare Royalty Partners to support the commercialization and expansion of its Meningitec, a recently acquired vaccine from Pfizer. Meningitec is an established commercial vaccine to prevent ...
Tags: Nuron Biotech, secured finance, vaccine, Meningitec, commercial vaccine
AMC Health will offer an array of telemonitoring services for clinical trial of lisinopril, which will be conducted by Transparency Life Sciences (TLS). US FDA has granted Investigational New Drug (IND) status to Lisinopril, which allows ...
Tags: AMC Health, Telemonitoring Services, clinical trial, Medicine
Health experts have urged food manufacturers to fortify more food with Vitamin D as the 19th century disease rickets returns to the UK. Rickets is caused by deficiency or impaired metabolism of vitamin D, phosphorus or calcium. Vitamin ...
Tags: Fortify Foods, Vitamin D, Rickets
The US Food and Drug Administration (FDA) has cleared Codman & Shurtleff's pre market approval (PMA) application of Medstream Programmable Infusion system, designed as a treatment for spasticity caused by stroke, cerebral palsy, multiple ...
Tags: FDA, Medstream Programmable Infusion system, Medstream system
Genzyme, a Sanofi company, has submitted a supplemental biologics license application (sBLA) to the FDA and marketing authorization application (MAA) to EMA for Lemtrada to treat relapsing multiple sclerosis (RMS). In collaboration with ...
Tags: sBLA, relapsing multiple sclerosis, RMS
The FDA has approved Genzyme, a Sanofi company, Aubagio (teriflunomide) as a new once-daily, oral treatment indicated for relapsing forms of multiple sclerosis (MS). Aubagio, an immunomodulator with anti-inflammatory properties, has shown ...
Tags: Aubagio, teriflunomide, new once-daily, oral treatment
The United States Patent and Trademark Office (USPTO) has issued notice of allowance for Avanir Pharmaceuticals' patent application covering Nuedexta. The patent application entitled, Pharmaceutical Compositions Comprising ...
Tags: USPTO, patent application, nuedexta, pseudobulbar affect
The Health Canada has approved a label change for Biogen Idec's Tysabri to include anti-JC virus (JCV) antibody status as a risk factor for patients with multiple sclerosis (MS). The product monograph change will help enable ...
Tags: label change, Health Canada, risk assessment
Nectid, a drug discovery company, has initiated clinical development of agomelatine for autism and pain indications in the US. Agomelatine, a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, is approved for the ...
Australian Therapeutic Goods Administration (TGA) has cleared Genzyme's once daily oral Aubagio 14mg dose for the treatment of relapsing multiple sclerosis (MS). Aubagio, which has anti-inflammatory properties, is expected to minimize ...
Genzyme, a Sanofi company, has received a refuse to file letter from the US Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of Lemtrada (alemtuzumab) as a treatment ...
Tags: Genzyme, Lemtrada marketing, FDA
Teva Pharmaceutical Industries has reported that the Glatiramer Acetate Low-Frequency Administration (GALA) study evaluating a new dose of glatiramer acetate injection (GA) met its primary endpoint. The Phase III trial evaluated the ...
Tags: Teva Pharmaceutical Industries, Medicine, glatiramer acetate injection
BOTOX Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval. BOTOX Cosmetic is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe ...
Tags: BOTOX Cosmetic, 10-year anniversary, FDA, frown lines, glabellar lines